
GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

